Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
View/ Open
Date
2016-08-28ICR Author
Author
van Wamel, A
Sontum, PC
Healey, A
Kvåle, S
Bush, N
Bamber, J
de Lange Davies, C
Type
Journal Article
Metadata
Show full item recordAbstract
Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong increase in therapeutic efficacy; 120days after study start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group and the median survival was increased by 86%. In combination with Abraxane® (12mg paclitaxel/kg given i.v.), ACT induced a strong increase in the therapeutic efficacy; 60days after study start 100% of the animals were in stable, remission vs. 0% for the Abraxane® only group, 120days after study start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane® only group. For the ACT+Abraxane group 100% of the animals were alive after 120days vs. 0% for the Abraxane® only group. Proof of concept for Acoustic Cluster Therapy has been demonstrated; ACT markedly increases the therapeutic efficacy of both paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
Collections
Subject
Cell Line, Tumor
Animals
Humans
Mice
Prostatic Neoplasms
Paclitaxel
Antineoplastic Combined Chemotherapy Protocols
Drug Delivery Systems
Male
Drug Liberation
Ultrasonic Waves
Albumin-Bound Paclitaxel
Research team
Ultrasound & Optical Imaging
Language
eng
Date accepted
2016-06-09
License start date
2016-08
Citation
Journal of controlled release : official journal of the Controlled Release Society, 2016, 236 pp. 15 - 21
Publisher
ELSEVIER SCIENCE BV